zilucoplan (Zilbrysq)
Jump to navigation
Jump to search
Indications
- generalized myasthenia gravis in adults who are acetylcholine receptor Ab positive (FDA-approved Oct 2023)
Dosage
- once daily subcutaneous injection 0.3 mg/kg
Adverse effects
Mechanism of action
- macrocyclic peptide that inhibits complement C5
More general terms
References
- ↑ Brooks M FDA Approves New Drug for Generalized Myasthenia Gravis. Medscape. Oct 18, 2023 https://www.medscape.com/viewarticle/997478
- ↑ Howard JF Jr, Bresch S, Genge A et al Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurology. 2023;22(5):P395-P406. May PMID: https://www.ncbi.nlm.nih.gov/pubmed/37059508 https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(23)00080-7/fulltext